2. Search Result
Search Result
Results for "

Rituximab

" in MedChemExpress (MCE) Product Catalog:

5

Inhibitors & Agonists

5

Inhibitory Antibodies

4

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P9913
    Rituximab
    Maximum Cited Publications
    6 Publications Verification

    Anti-Human CD20 type I, Chimeric Antibody

    		 Radionuclide-Drug Conjugates (RDCs) CD20 Inflammation/Immunology Cancer
    Rituximab is an anti-CD20 chimeric monoclonal antibody used for research of certain autoimmune diseases and cancer.
    Rituximab
  • HY-P9913A
    Rituximab (anti-CD20)
    Maximum Cited Publications
    6 Publications Verification

    		 CD20 Inflammation/Immunology Cancer
    Rituximab (anti-CD20) is an anti-CD20 chimeric monoclonal antibody used to treat certain autoimmune diseases and types of cancer .
    Rituximab (anti-CD20)
  • HY-P990033
    Anzurstobart

    CC-95251; BMS-986351

    		 CD47 Cancer
    Anzurstobart (CC-95251; BMS-986351) is a high-affinity, fully human monoclonal anti-SIRPα antibody that blocks the binding of CD47 to SIRPα. Anzurstobart enhances macrophage phagocytic activity against DLBCL cell lines in co-culture models when combined with the antibody Rituximab (HY-P9913). Anzurstobart has the potential for solid and hematologic malignancies research .
    Anzurstobart
  • HY-P99113
    Inebilizumab
    1 Publications Verification

    		 ADC Antibody CD19 Inflammation/Immunology
    Inebilizumab is an anti-CD19 monoclonal antibody (mAb) with enhanced antibody-dependent cell-mediated cytotoxicity against B cells. Inebilizumab can be used for multiple sclerosis and neuromyelitis optica research .
    Inebilizumab
  • HY-145448
    MC-VC-PABC-amide-PEG1-CH2-CC-885

    		E3 Ligase Ligand-Linker Conjugates Cancer
    MC-VC-PABC-amide-PEG1-CH2-CC-885 (compound III) is a neoDegrader, a conjugate of the GSPT1 degrader/molecular glue CC-885 (HY-101488) and a linker. MC-VC-PABC-amide-PEG1-CH2-CC-885 can be conjugated to the antibody DAR3.7 that specifically targets CD56 to synthesize Antibody-Drug Conjugates (ADCs). MC-VC-PABC-amide-PEG1-CH2-CC-885 can also be conjugated to Belantamab (HY-P9980), Daratumumab (HY-P9915), huMy9-6 IgG1, Indatuximab (HY-P990607), Isatuximab (HY-P9976), lintuzumab IgG1, Pertuzumab (HY-P9912), OR000213, Rituximab (HY-P9913), Sacituzumab (HY-P99045), Trastuzumab (HY-P9907)and U3-1784 (HY-P990672) to form conjugates .
    MC-VC-PABC-amide-PEG1-CH2-CC-885

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: